ARVN Stock Analysis: Arvinas | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 450m USD | 12M Return: -32.6% | US04335A1051 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 6.39M
Qual. Beats: 0
Rev. Trend: 56.7%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 8.1 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Arvinas is a clinical-stage biotechnology company that develops therapies based on targeted protein degradation, using its proprietary PROTAC (proteolysis targeting chimera) platform to eliminate disease-causing proteins rather than merely inhibit them. Unlike traditional small-molecule inhibitors that block protein activity temporarily, PROTACs recruit the cells natural ubiquitin-proteasome system to degrade target proteins, a modality that has attracted significant partnership interest from large pharmaceutical companies.
The companys pipeline spans neurodegenerative diseases, oncology, and rare disorders, with notable programs including ARV-102 targeting LRRK2 for Parkinsons disease and progressive supranuclear palsy, ARV-806 targeting KRAS G12D-mutant cancers, and vepdegestrant, an estrogen receptor degrader for ER+/HER2- breast cancer. Arvinas also has collaborations with major pharmaceutical partners including Pfizer, Genentech/Roche, and Bayer, which provide development funding and validation of its platform. Founded in 2013 and headquartered in New Haven, Connecticut, the company went public in 2018 and operates as a small-cap clinical biotech, meaning it is not yet generating commercial product revenue and relies on partnerships and capital markets to fund its research and development activities.
- Vepdegestrant Phase 3 breast cancer data with Pfizer
- ARV-102 Parkinsons and ARV-806 KRAS trial readouts
- Cash burn and dilution risk as trials advance
| Net Income: -9.50m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.26 > 0.02 and ΔFCF/TA 12.72 > 1.0 |
| NWC/Revenue: 188.0% < 20% (prev 218.2%; Δ -30.17% < -1%) |
| CFO/TA -0.26 > 3% & CFO -158.3m > Net Income -9.50m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 8.39 > 1.5 & < 3 |
| Outstanding Shares: last quarter (65.4m) vs 12m ago -10.29% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 37.93% > 50% (prev 36.99%; Δ 0.94% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.85 (Total Current Assets 587.6m - Total Current Liabilities 70.0m) / Total Assets 607.5m |
| B: -2.56 (Retained Earnings -1.55b / Total Assets 607.5m) |
| C: -0.03 (EBIT TTM -25.2m / Avg Total Assets 725.9m) |
| D: 5.48 (Book Value of Equity 513.8m / Total Liabilities 93.7m) |
| Altman-Z'' = 2.77 = A |
| DSRI: 0.22 (Receivables 5.30m/26.8m, Revenue 275.3m/312.3m) |
| GMI: 1.02 (GM 97.89% / 95.86%) |
| AQI: 3.03 (AQ_t 0.01 / AQ_t-1 0.00) |
| SGI: 0.88 (Revenue 275.3m / 312.3m) |
| TATA: 0.24 (NI -9.50m - CFO -158.3m) / TA 607.5m) |
| Beneish M = -2.50 (Cap -4..+1) = A |
As of November 15, 2026, the stock is trading at USD 6.82 with a total of 879,353 shares traded. Over the past week, the price has changed by +6.40%, over one month by -0.29%, over three months by -24.31% and over the past year by -32.61%.
Current recommended Stop Loss: 6.20 (which is 9.1% or 1.4 ATR below the current price).
Arvinas has received a consensus analysts rating of 3.80. Therefore, it is recommended to hold ARVN.
- StrongBuy: 5
- Buy: 2
- Hold: 8
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 14 | 105.3% |
P/E Forward = 17.8571
P/S = 1.6342
P/B = 0.8801
Revenue TTM = 275.3m USD
EBIT TTM = -25.2m USD
EBITDA TTM = -20.6m USD
Long Term Debt = 200k USD (from longTermDebt, last quarter)
Short Term Debt = 2.10m USD (from shortTermDebt, last quarter)
Debt = 14.8m USD (from shortLongTermDebtTotal, last quarter) + Leases 7.20m
Net Debt = -543.6m USD (calculated: Debt 14.8m - CCE 558.4m)
Enterprise Value = 449.9m USD (floored to Market Cap, CCE > MCap+Debt)
Interest Coverage Ratio = unknown (Ebit TTM -25.2m / Interest Expense TTM 0.0)
EV/FCF = -2.82x (Enterprise Value 449.9m / FCF TTM -159.8m)
FCF Yield = -35.52% (FCF TTM -159.8m / Enterprise Value 449.9m)
FCF Margin = -58.05% (FCF TTM -159.8m / Revenue TTM 275.3m)
Net Margin = -3.45% (Net Income TTM -9.50m / Revenue TTM 275.3m)
Gross Margin = unknown ((Revenue TTM 275.3m - Cost of Revenue TTM 11.4m) / Revenue TTM)
Tobins Q-Ratio = 0.74 (Enterprise Value 449.9m / Total Assets 607.5m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 14.8m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -19.9m (EBIT -25.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.39 (Total Current Assets 587.6m / Total Current Liabilities 70.0m)
Debt / Equity = 0.03 (Debt 14.8m / totalStockholderEquity, last quarter 513.8m)
Debt / EBITDA = 26.39 (negative EBITDA) (Net Debt -543.6m / EBITDA -20.6m)
Debt / FCF = 3.40 (negative FCF - burning cash) (Net Debt -543.6m / FCF TTM -159.8m)
Total Stockholder Equity = 474.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -1.31% (Net Income -9.50m / Total Assets 607.5m)
RoE = -2.00% (Net Income TTM -9.50m / Total Stockholder Equity 474.1m)
RoCE = -5.31% (EBIT -25.2m / Capital Employed (Equity 474.1m + L.T.Debt 200k))
RoIC = -3.79% (negative operating profit) (NOPAT -19.9m / Invested Capital 525.8m)
WACC = 10.69% (E(449.9m)/V(464.7m) * Re(11.04%) + D(14.8m)/V(464.7m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 11.04% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -78.98 | Cagr: -4.12%
[DCF] Fair Price = unknown (Cash Flow -159.8m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.02 | # QB: 0
Revenue Correlation: 56.70 | Revenue CAGR: 51.58% | SUE: -0.21 | # QB: 0
EPS current Quarter (2027-03-31): EPS=-0.79 | Chg30d=+12.10% | Revisions=-25% | Analysts=5
EPS current Year (2026-12-31): EPS=0.16 | Chg30d=+216.13% | Revisions=+36% | GrowthEPS=+114.0% | GrowthRev=+5.7%
EPS next Year (2027-12-31): EPS=-3.18 | Chg30d=+1.71% | Revisions=+0% | GrowthEPS=-2096.1% | GrowthRev=-82.8%
[Analyst] Revisions Ratio: +14% (up=11, down=8)